Zug, Switzerland, June 14, 2016 – Amneal Pharmaceuticals Company GmbH (“Amneal”), an
affiliate of Amneal Pharmaceuticals LLC, a leading generics manufacturer, today announced the
execution of an exclusive development and license agreement with Iconovo AB, a developer of
dry powder inhalers. Under the agreement, Amneal will leverage Iconovo’s reservoir inhaler,
ICOres, and dry powder formulation for a generic inhalation product to treat asthma and chronic
obstructive pulmonary disease (COPD). This collaboration will complement Amneal’s current
pipeline of inhalation products in markets outside the United States. Amneal expects to
manufacture these products in its Cashel, Ireland facility in the future. Additionally, Amneal
continues to develop inhalation products for the U.S. markets through its internal R&D, with
several products in advanced stages of development.